Schechter Investment Advisors LLC Sells 117 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schechter Investment Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 855 shares of the biopharmaceutical company’s stock after selling 117 shares during the period. Schechter Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $609,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Grandfield & Dodd LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the 4th quarter. Grandfield & Dodd LLC now owns 32,596 shares of the biopharmaceutical company’s stock worth $23,219,000 after acquiring an additional 268 shares during the period. LGT Fund Management Co Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 23.9% during the 4th quarter. LGT Fund Management Co Ltd. now owns 560 shares of the biopharmaceutical company’s stock worth $399,000 after acquiring an additional 108 shares during the period. Plato Investment Management Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 4th quarter. Plato Investment Management Ltd now owns 2,661 shares of the biopharmaceutical company’s stock worth $1,902,000 after acquiring an additional 44 shares during the period. Bellecapital International Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 44.1% during the 4th quarter. Bellecapital International Ltd. now owns 19,600 shares of the biopharmaceutical company’s stock worth $13,962,000 after acquiring an additional 6,002 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $464,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ:REGN opened at $675.49 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a 50 day moving average of $697.13 and a 200-day moving average of $859.13. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market cap of $73.85 billion, a price-to-earnings ratio of 17.65, a P/E/G ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on REGN. TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.